Delivery Order SPE2DR25D3014-SPE2DR26FP1EY
- Not listed
- The Defense Logistics Agency awarded a $3,819.87 delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,282.30 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply) on November 24, 2025, with an ultimate completion date of November 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,169.83 to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count). This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers....
- The Defense Logistics Agency awarded a delivery order valued at $1,087.30 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-25 mg tablets (90-count supply) on November 26, 2025, with completion scheduled for November 28, 2025. This is a firm fixed price delivery order with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under a competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) under a firm fixed-price contract with a ceiling value of $2,530.91. The award was issued on November 7, 2025, with an ultimate completion date of November 10, 2025. This non-competitive delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a contract ceiling value of $11,676.65. This is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) with a ceiling value of $16,944.57. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 12, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,892.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 80-12.5 mg tablets in quantities of 90, with delivery to conclude by December 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a routine pharmaceutical procurement supporting federal medical supply needs. The work will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-12.5 mg tablets (90-count supply) under a firm fixed-price contract valued at $4,916.53, with completion targeted for December 8, 2025. This non-set-aside award was issued on December 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count package) at a ceiling value of $3,756.36. This firm fixed price delivery order represents a non-competitive set-aside and is scheduled for completion by September 12, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, leveraging the company's established...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1EYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count units) valued at $11,211.06. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of December 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was competed among all eligible vendors. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999 prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical support to military healthcare systems globally. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and supplies a broad range of medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.2k | 12/2/25 |